newsfilter
← Latest News
GlobeNewswire·

Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

  • Tempest Therapeutics exercised its option to secure exclusive global rights outside China to Hebei Senlang's CD7-targeted lentiviral platform & in vivo CAR-T portfolio.
  • The lead candidate TPST-4903 (formerly SL4903) is a BCMA/GPRC5D dual-targeting in vivo CAR-T therapy currently evaluated in 13 patients with relapsed or refractory multiple myeloma.
  • Preliminary clinical data from the DELIVER-1 Phase 1 study, including results from patients with extramedullary disease & prior CAR-T exposure, are encouraging & support further evaluation.
  • Tempest plans to present detailed findings from the study at a major scientific conference after additional follow-up characterizes the benefit-risk profile.
  • The licensed lentiviral platform complements Tempest's existing lipid nanoparticle (LNP) delivery system to enable in vivo generation of antigen-directed CAR-T cells.
  • The agreement provides access to additional in vivo CAR-T candidates for potential development in blood cancers, solid tumors, & autoimmune conditions.
Company
Tempest Therapeutics
Keywords
Nasdaq:TPST, Tempest Therapeutics